Top Stories
Immuneering will supply its investigational MEK inhibitor atebimetinib (IMM-1-104) to two Astellas studies targeting patients with CLDN18.2-postive pancreatic cancer. Financial terms of the clinical c...
No new vouchers have been awarded since May, according to a Reuters report, raising questions about the future of the drug review initiative.
Chief Medical officer Cristian Massacesi will take charge in January, with Chief Research Officer Robert Plenge set to leave.
The Chinese firm is developing radiopharmaceutical assets targeting oncology and neurological disorders, several of which are lined up for IND submissions.
The spin-off from Addex Therapeutics is developing NTX-253, an oral muscarinic M4 positive allosteric modulator, for schizophrenia.
Conference News
Six MIMRYLO™ (rusfertide) abstracts demonstrate improvement in patient-reported outcomes (PROs) and efficacy and safety across patient subgroupsOral presentation of Phase 2 elritercept data highlight...
CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modif...
BMS brings discovery and development under one roofBristol Myers Squibb announced a restructuring that will bring its discovery and development teams under a single R&D umbrella. Chief Medical Officer...
- Topline Primary Endpoint Results of the Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia Following the 80th Event to Report this Month -- 40 Patients Enrolled in Phase 2 Trial o...
SP001, an anti-CD40L antibody with potential across multiple immune-mediated diseases, advancing toward Phase 2 initiation in Immunoglobulin G4-related disease (IgG4-RD)Cash and cash equivalents of $1...
